Triple Reuptake Inhibitors as Potential Next-Generation Antidepressants: A New Hope?

References

• Belmaker RH , AgamG. Major depressive disorder. N. Engl. J. Med.358 (1), 55–68 (2008).
   PubMed Web of Science ®Google Scholar
• American Psychiatric Association . Diagnostic and Statistical Manual of Mental Disorders ((4th Edition)). American Psychiatric Association, Washington, DC, USA (2000).
   Google Scholar
• Gold PW , ChrousosGP. The endocrinology of melancholic and atypical depression: relation to neurocircuitry and somatic consequences. Proc. Assoc. Am. Physicians111 (1), 22–34 (1999).
   PubMedGoogle Scholar
• Millan MJ . Dual- and triple-acting agents for treating core and co-morbid symptoms of major depression: novel concepts, new drugs. Neurotherapeutics6 (1), 53–77 (2009).
   PubMed Web of Science ®Google Scholar
• Whiteford HA , DegenhardtL, RehmJet al. Global burden of disease attributable to mental and substance use disorders: findings from the Global Burden of Disease Study 2010. Lancet382 (9904), 1575–1586 (2013).
   PubMed Web of Science ®Google Scholar
• Blendy JA . The role of CREB in depression and antidepressant treatment. Biol. Psychiatry59 (12), 1144–1150 (2006).
   PubMed Web of Science ®Google Scholar
• Shimon H , AgamG, BelmakerRH, HydeTM, KleinmanJE. Reduced frontal cortex inositol levels in postmortem brain of suicide victims and patients with bipolar disorder. Am. J. Psychiatry154 (8), 1148–1150 (1997).
   PubMed Web of Science ®Google Scholar
• Coupland NJ , OgilvieCJ, HegadorenKM, SeresP, HanstockCC, AllenPS. Decreased prefrontal myo-inositol in major depressive disorder. Biol. Psychiatry57 (12), 1526–1534 (2005).
   PubMed Web of Science ®Google Scholar
• Coppen A . The biochemistry of affective disorders. Br. J. Psychiatry113 (504), 1237–1264 (1967).
   PubMed Web of Science ®Google Scholar
• Hensler JG . Regulation of 5-HT1A receptor function in brain following agonist or antidepressant administration. Life Sci.72 (15), 1665–1682 (2003).
   PubMed Web of Science ®Google Scholar
• Linnoila M , VirkkunenM, ScheininM, NuutilaA, RimonR, GoodwinFK. Low cerebrospinal fluid 5-hydroxyindoleacetic acid concentration differentiates impulsive from nonimpulsive violent behavior. Life Sci.33 (26), 2609–2614 (1983).
   PubMed Web of Science ®Google Scholar
• Handley SL . 5-Hydroxytryptamine pathways in anxiety and its treatment. Pharmacol. Ther.66 (1), 103–148 (1995).
   PubMed Web of Science ®Google Scholar
• Morilak DA , FrazerA. Antidepressants and brain monoaminergic systems: a dimensional approach to understanding their behavioural effects in depression and anxiety disorders. Int. J. Neuropsychopharmacol.7 (2), 193–218 (2004).
   PubMed Web of Science ®Google Scholar
• Racagni G , BrunelloN. Physiology to functionality: the brain and neurotransmitter activity. Int. Clin. Psychopharmacol.14 (Suppl. 1), S3–S7 (1999).
   PubMedGoogle Scholar
• Sanacora G , ZarateCA, KrystalJH, ManjiHK. Targeting the glutamatergic system to develop novel, improved therapeutics for mood disorders. Nat. Rev. Drug Discov.7 (5), 426–437 (2008).
   PubMed Web of Science ®Google Scholar
• Hasler G , Van Der VeenJW, TumonisT, MeyersN, ShenJ, DrevetsWC. Reduced prefrontal glutamate/glutamine and gamma-aminobutyric acid levels in major depression determined using proton magnetic resonance spectroscopy. Arch. Gen. Psychiatry64 (2), 193–200 (2007).
   PubMed Web of Science ®Google Scholar
• Lewy AJ , LeflerBJ, EmensJS, BauerVK. The circadian basis of winter depression. Proc. Natl Acad. Sci. USA103 (19), 7414–7419 (2006).
   PubMed Web of Science ®Google Scholar
• Beasley CL , HonerWG, BergmannK, FalkaiP, LutjohannD, BayerTA. Reductions in cholesterol and synaptic markers in association cortex in mood disorders. Bipolar Disord.7 (5), 449–455 (2005).
   PubMed Web of Science ®Google Scholar
• Bymaster FP , FelderCC. Role of the cholinergic muscarinic system in bipolar disorder and related mechanism of action of antipsychotic agents. Mol. Psychiatry7 (Suppl. 1), S57–S63 (2002).
   PubMedGoogle Scholar
• Kennedy SE , KoeppeRA, YoungEA, ZubietaJK. Dysregulation of endogenous opioid emotion regulation circuitry in major depression in women. Arch. Gen. Psychiatry63 (11), 1199–1208 (2006).
   PubMed Web of Science ®Google Scholar
• Sullivan GM , MannJJ, OquendoMA, LoES, CooperTB, GormanJM. Low cerebrospinal fluid transthyretin levels in depression: correlations with suicidal ideation and low serotonin function. Biol. Psychiatry60 (5), 500–506 (2006).
   PubMed Web of Science ®Google Scholar
• Aan Het Rot M , ZarateCAJr, CharneyDS, MathewSJ. Ketamine for depression: where do we go from here?Biol. Psychiatry72 (7), 537–547 (2012).
   PubMed Web of Science ®Google Scholar
• Berman RM , CappielloA, AnandAet al. Antidepressant effects of ketamine in depressed patients. Biol. Psychiatry47 (4), 351–354 (2000).
   PubMed Web of Science ®Google Scholar
• Hediger MA , RomeroMF, PengJB, RolfsA, TakanagaH, BrufordEA. The ABCs of solute carriers: physiological, pathological and therapeutic implications of human membrane transport proteins introduction. Pflugers Arch.447 (5), 465–468 (2004).
   PubMed Web of Science ®Google Scholar
• Guastella J , NelsonN, NelsonHet al. Cloning and expression of a rat brain GABA transporter. Science249 (4974), 1303–1306 (1990).
   PubMed Web of Science ®Google Scholar
• Hoffman BJ , MezeyE, BrownsteinMJ. Cloning of a serotonin transporter affected by antidepressants. Science254 (5031), 579–580 (1991).
   PubMed Web of Science ®Google Scholar
• Kilty JE , LorangD, AmaraSG. Cloning and expression of a cocaine-sensitive rat dopamine transporter. Science254 (5031), 578–579 (1991).
   PubMed Web of Science ®Google Scholar
• Pacholczyk T , BlakelyRD, AmaraSG. Expression cloning of a cocaine- and antidepressant-sensitive human noradrenaline transporter. Nature350 (6316), 350–354 (1991).
   PubMed Web of Science ®Google Scholar
• Bismuth Y , KavanaughMP, KannerBI. Tyrosine 140 of the gamma-aminobutyric acid transporter GAT-1 plays a critical role in neurotransmitter recognition. J. Biol. Chem.272 (26), 16096–16102 (1997).
   PubMed Web of Science ®Google Scholar
• Kitayama S , ShimadaS, XuH, MarkhamL, DonovanDM, UhlGR. Dopamine transporter site-directed mutations differentially alter substrate transport and cocaine binding. Proc. Natl Acad. Sci. USA89 (16), 7782–7785 (1992).
   PubMed Web of Science ®Google Scholar
• Chen JG , RudnickG. Permeation and gating residues in serotonin transporter. Proc. Natl Acad. Sci. USA97 (3), 1044–1049 (2000).
   PubMed Web of Science ®Google Scholar
• Yamashita A , SinghSK, KawateT, JinY, GouauxE. Crystal structure of a bacterial homologue of Na+/Cl-dependent neurotransmitter transporters. Nature437 (7056), 215–223 (2005).
   PubMed Web of Science ®Google Scholar
• Zhou Z , ZhenJ, KarpowichNKet al. LeuT-desipramine structure reveals how antidepressants block neurotransmitter reuptake. Science317 (5843), 1390–1393 (2007).
   PubMed Web of Science ®Google Scholar
• Singh SK , YamashitaA, GouauxE. Antidepressant binding site in a bacterial homologue of neurotransmitter transporters. Nature448 (7156), 952–956 (2007).
   PubMed Web of Science ®Google Scholar
• Singh SK , PiscitelliCL, YamashitaA, GouauxE. A competitive inhibitor traps LeuT in an open-to-out conformation. Science322 (5908), 1655–1661 (2008).
   PubMed Web of Science ®Google Scholar
• Zhou Z , ZhenJ, KarpowichNK, LawCJ, ReithME, WangDN. Antidepressant specificity of serotonin transporter suggested by three LeuT-SSRI structures. Nat. Struct. Mol. Biol.16 (6), 652–657 (2009).
   PubMed Web of Science ®Google Scholar
• Krishnamurthy H , GouauxE. X-ray structures of LeuT in substrate-free outward-open and apo inward-open states. Nature481 (7382), 469–474 (2012).
   PubMed Web of Science ®Google Scholar
• Kristensen AS , AndersenJ, JorgensenTNet al. SLC6 neurotransmitter transporters: structure, function, and regulation. Pharmacol. Rev.63 (3), 585–640 (2011).
   PubMed Web of Science ®Google Scholar
• Ban TA . The role of serendipity in drug discovery. Dialogues Clin. Neurosci.8 (3), 335–344 (2006).
   PubMedGoogle Scholar
• Shulman KI , HerrmannN, WalkerSE. Current place of monoamine oxidase inhibitors in the treatment of depression. CNS Drugs27 (10), 789–797 (2013).
   PubMed Web of Science ®Google Scholar
• Deftereos SN , DodouE, AndronisC, PersidisA. From depression to neurodegeneration and heart failure: re-examining the potential of MAO inhibitors. Expert Rev. Clin. Pharmacol.5 (4), 413–425 (2012).
   PubMed Web of Science ®Google Scholar
• Rose JB . Tricyclic antidepressant toxicity. Clin. Toxicol.11 (4), 391–402 (1977).
   PubMed Web of Science ®Google Scholar
• Spinks D , SpinksG. Serotonin reuptake inhibition: an update on current research strategies. Curr. Med. Chem.9 (8), 799–810 (2002).
   PubMed Web of Science ®Google Scholar
• Wong DT , BymasterFP. Development of antidepressant drugs. Fluoxetine (prozac) and other selective serotonin uptake inhibitors. Adv. Exp. Med. Biol.363, 77–95 (1995).
   PubMedGoogle Scholar
• Hiemke C , HartterS. Pharmacokinetics of selective serotonin reuptake inhibitors. Pharmacol. Ther.85 (1), 11–28 (2000).
   PubMed Web of Science ®Google Scholar
• Owens MJ , NemeroffCB. The serotonin transporter and depression. Depress. Anxiety8 (Suppl. 1), 5–12 (1998).
   PubMedGoogle Scholar
• Di Giovanni G , EspositoE, Di MatteoV. Role of serotonin in central dopamine dysfunction. CNS Neurosci. Ther.16 (3), 179–194 (2010).
   PubMed Web of Science ®Google Scholar
• Wenthur CJ , BennettMR, LindsleyCW. Classics in chemical neuroscience: fluoxetine (prozac). ACS Chem. Neurosci.5 (1), 14–23 (2014).
   Web of Science ®Google Scholar
• Danish University Antidepressant Group . Citalopram: clinical effect profile in comparison with clomipramine. A controlled multicenter study. Psychopharmacology (Berl.)90 (1), 131–138 (1986).
   PubMed Web of Science ®Google Scholar
• Thase ME , EntsuahAR, RudolphRL. Remission rates during treatment with venlafaxine or selective serotonin reuptake inhibitors. Br. J. Psychiatry178, 234–241 (2001).
   PubMed Web of Science ®Google Scholar
• Nemeroff CB , EntsuahR, BenattiaI, DemitrackM, SloanDM, ThaseME. Comprehensive analysis of remission (COMPARE) with venlafaxine versus SSRIs. Biol. Psychiatry63 (4), 424–434 (2008).
   PubMed Web of Science ®Google Scholar
• Garnock-Jones KP , KeatingGM. Atomoxetine: a review of its use in attention-deficit hyperactivity disorder in children and adolescents. Paediatr. Drugs11 (3), 203–226 (2009).
   PubMedGoogle Scholar
• Ratner S , LaorN, BronsteinY, WeizmanA, TorenP. Six-week open-label reboxetine treatment in children and adolescents with attention-deficit/hyperactivity disorder. J. Am. Acad. Child Adolesc. Psychiatry44 (5), 428–433 (2005).
   PubMed Web of Science ®Google Scholar
• Breder CD . US 20100069390 A1 (2010).
   Google Scholar
• Barbey JT , RooseSP. SSRI safety in overdose. J. Clin. Psychiatry59 (Suppl. 15), 42–48 (1998).
   PubMed Web of Science ®Google Scholar
• Goldstein BJ , GoodnickPJ. Selective serotonin reuptake inhibitors in the treatment of affective disorders – III. Tolerability, safety and pharmacoeconomics. J. Psychopharmacol.12 (3 Suppl. B), S55–S87 (1998).
   PubMed Web of Science ®Google Scholar
• Gumnick JF , NemeroffCB. Problems with currently available antidepressants. J. Clin. Psychiatry61 (Suppl. 10), 5–15 (2000).
   PubMedGoogle Scholar
• Steffens DC , KrishnanKR, HelmsMJ. Are SSRIs better than TCAs? Comparison of SSRIs and TCAs: a meta-analysis. Depress. Anxiety6 (1), 10–18 (1997).
   PubMedGoogle Scholar
• Rush AJ , TrivediMH, WisniewskiSRet al. Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report. Am. J. Psychiatry163 (11), 1905–1917 (2006).
   PubMed Web of Science ®Google Scholar
• Andersen J , KristensenAS, Bang-AndersenB, StromgaardK. Recent advances in the understanding of the interaction of antidepressant drugs with serotonin and norepinephrine transporters. Chem. Commun. (Camb.) (25), 3677–3692 (2009).
   PubMed Web of Science ®Google Scholar
• Tatsumi M , GroshanK, BlakelyRD, RichelsonE. Pharmacological profile of antidepressants and related compounds at human monoamine transporters. Eur. J. Pharmacol.340 (2–3), 249–258 (1997).
   PubMed Web of Science ®Google Scholar
• Auclair AL , MartelJC, AssieMBet al. Levomilnacipran (F2695), a norepinephrine-preferring SNRI: profile in vitro and in models of depression and anxiety. Neuropharmacology70, 338–347 (2013).
   PubMed Web of Science ®Google Scholar
• Owen RT . Vilazodone: a new treatment option for major depressive disorder. Drugs Today (Barc.)47 (7), 531–537 (2011).
   PubMed Web of Science ®Google Scholar
• Citrome L . Vortioxetine for major depressive disorder: a systematic review of the efficacy and safety profile for this newly approved antidepressant - what is the number needed to treat, number needed to harm and likelihood to be helped or harmed?Int. J. Clin. Pract.68 (1), 60–82 (2014).
   PubMed Web of Science ®Google Scholar
• D’Aquila PS , ColluM, GessaGL, SerraG. The role of dopamine in the mechanism of action of antidepressant drugs. Eur. J. Pharmacol.405 (1–3), 365–373 (2000).
   PubMed Web of Science ®Google Scholar
• Papakostas GI . Dopaminergic-based pharmacotherapies for depression. Eur. Neuropsychopharmacol.16 (6), 391–402 (2006).
   PubMed Web of Science ®Google Scholar
• Dunlop BW , NemeroffCB. The role of dopamine in the pathophysiology of depression. Arch. Gen. Psychiatry64 (3), 327–337 (2007).
   PubMed Web of Science ®Google Scholar
• Nutt D , DemyttenaereK, JankaZet al. The other face of depression, reduced positive affect: the role of catecholamines in causation and cure. J. Psychopharmacol.21 (5), 461–471 (2007).
   PubMed Web of Science ®Google Scholar
• Mcdonald WM , RichardIH, DelongMR. Prevalence, etiology, and treatment of depression in Parkinson’s disease. Biol. Psychiatry54 (3), 363–375 (2003).
   PubMed Web of Science ®Google Scholar
• Brown AS , GershonS. Dopamine and depression. J. Neural. Transm. Gen. Sect.91 (2–3), 75–109 (1993).
   PubMed Web of Science ®Google Scholar
• Nestler EJ , CarlezonWAJr. The mesolimbic dopamine reward circuit in depression. Biol. Psychiatry59 (12), 1151–1159 (2006).
   PubMed Web of Science ®Google Scholar
• Willner P . Dopamine and depression: a review of recent evidence. I. Empirical studies. Brain Res.287 (3), 211–224 (1983).
   PubMedGoogle Scholar
• Mischoulon D , NierenbergAA, KizilbashL, RosenbaumJF, FavaM. Strategies for managing depression refractory to selective serotonin reuptake inhibitor treatment: a survey of clinicians. Can. J. Psychiatry45 (5), 476–481 (2000).
   PubMed Web of Science ®Google Scholar
• Ascher JA , ColeJO, ColinJNet al. Bupropion: a review of its mechanism of antidepressant activity. J. Clin. Psychiatry56 (9), 395–401 (1995).
   PubMed Web of Science ®Google Scholar
• Reneric JP , LuckiI. Antidepressant behavioral effects by dual inhibition of monoamine reuptake in the rat forced swimming test. Psychopharmacology (Berl.)136 (2), 190–197 (1998).
   PubMed Web of Science ®Google Scholar
• Prica C , HascoetM, BourinM. Is co-administration of bupropion with SSRIs and SNRIs in forced swimming test in mice, predictive of efficacy in resistant depression?Behav. Brain Res.194 (1), 92–99 (2008).
   PubMed Web of Science ®Google Scholar
• Sporn J , GhaemiSN, SamburMRet al. Pramipexole augmentation in the treatment of unipolar and bipolar depression: a retrospective chart review. Ann. Clin. Psychiatry12 (3), 137–140 (2000).
   PubMedGoogle Scholar
• Brocco M , DekeyneA, PappM, MillanMJ. Antidepressant-like properties of the anti-parkinson agent, piribedil, in rodents: mediation by dopamine D2 receptors. Behav. Pharmacol.17 (7), 559–572 (2006).
   PubMed Web of Science ®Google Scholar
• Kinney JL . Nomifensine maleate: a new second-generation antidepressant. Clin. Pharm.4 (6), 625–636 (1985).
   PubMedGoogle Scholar
• Marks DM , PaeCU, PatkarAA. Triple reuptake inhibitors: the next generation of antidepressants. Curr. Neuropharmacol.6 (4), 338–343 (2008).
   PubMed Web of Science ®Google Scholar
• Guiard BP , El MansariM, BlierP. Prospect of a dopamine contribution in the next generation of antidepressant drugs: the triple reuptake inhibitors. Curr. Drug Targets10 (11), 1069–1084 (2009).
   PubMed Web of Science ®Google Scholar
• Fava M , RankinM. Sexual functioning and SSRIs. J. Clin. Psychiatry63 (Suppl. 5), 13–16; discussion 23–15 (2002).
   PubMedGoogle Scholar
• Gitlin MJ , SuriR, AltshulerL, Zuckerbrow-MillerJ, FairbanksL. Bupropion-sustained release as a treatment for SSRI-induced sexual side effects. J. Sex Marital. Ther.28 (2), 131–138 (2002).
   PubMed Web of Science ®Google Scholar
• Prins J , OlivierB, KorteSM. Triple reuptake inhibitors for treating subtypes of major depressive disorder: the monoamine hypothesis revisited. Expert Opin. Investig. Drugs20 (8), 1107–1130 (2011).
   PubMed Web of Science ®Google Scholar
• Dutta AK , MeltzerPC, MadrasBK. Positional importance of the nitrogen atom in novel piperidine analogues of GBR 12909: affinity and selectivity for the dopamine transporter. Med. Chem. Res.3 (4), 209–222 (1993).
   Google Scholar
• Dutta AK , XuC, ReithME. Structure-activity relationship studies of novel 4-[2-[bis(4-fluorophenyl)methoxy]ethyl]-1-(3-phenylpropyl)piperidine analogs: synthesis and biological evaluation at the dopamine and serotonin transporter sites. J. Med. Chem.39 (3), 749–756 (1996).
   PubMed Web of Science ®Google Scholar
• Dutta AK , CoffeyLL, ReithME. Highly selective, novel analogs of 4-[2-(diphenylmethoxy)ethyl]- 1-benzylpiperidine for the dopamine transporter: effect of different aromatic substitutions on their affinity and selectivity. J. Med. Chem.40 (1), 35–43 (1997).
   PubMed Web of Science ®Google Scholar
• Dutta AK , XuC, ReithME. Tolerance in the replacement of the benzhydrylic O atom in 4-[2-(diphenylmethoxy)ethyl]-1-benzylpiperidine derivatives by an N atom: development of new-generation potent and selective N-analogue molecules for the dopamine transporter. J. Med. Chem.41 (17), 3293–3297 (1998).
   PubMed Web of Science ®Google Scholar
• Dutta AK , DavisMC, ReithME. Rational design and synthesis of novel 2,5-disubstituted cis- and trans-piperidine derivatives exhibiting differential activity for the dopamine transporter. Bioorg. Med. Chem. Lett.11 (17), 2337–2340 (2001).
   PubMed Web of Science ®Google Scholar
• Ghorai SK , CookC, DavisMet al. High affinity hydroxypiperidine analogues of 4-(2-benzhydryloxyethyl)-1-(4-fluorobenzyl)piperidine for the dopamine transporter: stereospecific interactions in vitro and in vivo. J. Med. Chem.46 (7), 1220–1228 (2003).
   PubMed Web of Science ®Google Scholar
• Kolhatkar RB , GhoraiSK, GeorgeC, ReithME, DuttaAK. Interaction of cis-(6-benzhydrylpiperidin-3-yl)benzylamine analogues with monoamine transporters: structure-activity relationship study of structurally constrained 3,6-disubstituted piperidine analogues of (2,2-diphenylethyl)-[1-(4-fluorobenzyl)piperidin-4-ylmethyl]amine. J. Med. Chem.46 (11), 2205–2215 (2003).
   PubMed Web of Science ®Google Scholar
• Zhang S , ReithME, DuttaAK. Design, synthesis, and activity of novel cis- and trans-3,6-disubstituted pyran biomimetics of 3,6-disubstituted piperidine as potential ligands for the dopamine transporter. Bioorg. Med. Chem. Lett.13 (9), 1591–1595 (2003).
   PubMed Web of Science ®Google Scholar
• Skolnick P , PopikP, JanowskyA, BeerB, LippaAS. Antidepressant-like actions of DOV 21,947: a “triple” reuptake inhibitor. Eur. J. Pharmacol.461 (2–3), 99–104 (2003).
   PubMed Web of Science ®Google Scholar
• Skolnick P , PopikP, JanowskyA, BeerB, LippaAS. “Broad spectrum” antidepressants: is more better for the treatment of depression?Life Sci.73 (25), 3175–3179 (2003).
   PubMed Web of Science ®Google Scholar
• Zhang S , ZhenJ, ReithME, DuttaAK. Structural requirements for 2,4- and 3,6-disubstituted pyran biomimetics of cis-(6-benzhydryl-piperidin-3-yl)-benzylamine compounds to interact with monoamine transporters. Bioorg. Med. Chem.12 (23), 6301–6315 (2004).
   PubMed Web of Science ®Google Scholar
• Zhang S , ZhenJ, ReithME, DuttaAK. Discovery of novel trisubstituted asymmetric derivatives of (2s,4r,5r)-2-benzhydryl-5-benzylaminotetrahydropyran-4-ol, exhibiting high affinity for serotonin and norepinephrine transporters in a stereospecific manner. J. Med. Chem.48 (15), 4962–4971 (2005).
   PubMed Web of Science ®Google Scholar
• Zhang S , FernandezF, HazeldineSet al. Further structural exploration of trisubstituted asymmetric pyran derivatives (2S,4R,5R)-2-benzhydryl-5-benzylamino-tetrahydropyran-4-ol and their corresponding disubstituted (3S,6S) pyran derivatives: a proposed pharmacophore model for high-affinity interaction with the dopamine, serotonin, and norepinephrine transporters. J. Med. Chem.49 (14), 4239–4247 (2006).
   PubMed Web of Science ®Google Scholar
• Santra S , GogoiS, GopishettyBet al. Structural exploration of (3S,6S)-6-benzhydryl-n-benzyltetrahydro-2h-pyran-3-amine analogues: identification of potent triple monoamine reuptake inhibitors as potential antidepressants. Chem. Med. Chem.7 (12), 2093–2100 (2012).
   Google Scholar
• Gopishetty B , HazeldineS, SantraSet al. Further structure-activity relationship studies on 4-((((3s,6s)-6-benzhydryltetrahydro-2h-pyran-3-yl)amino)methyl)phenol: identification of compounds with triple uptake inhibitory activity as potential antidepressant agents. J. Med. Chem.54 (8), 2924–2932 (2011).
   PubMed Web of Science ®Google Scholar
• Dutta AK , SantraS, SharmaHet al. Pharmacological and behavioral characterization of D-473, an orally active triple reuptake inhibitor targeting dopamine, serotonin and norepinephrine transporters. PLoS ONE9 (11), e113420 (2014).
   PubMed Web of Science ®Google Scholar
• Dutta AK , GopishettyB, GogoiS, AliS, ZhenJ, ReithM. The novel trisubstituted pyran derivative D-142 has triple monoamine reuptake inhibitory activity and exerts potent antidepressant-like activity in rodents. Eur. J. Pharmacol.671 (1–3), 39–44 (2011).
   PubMed Web of Science ®Google Scholar
• Sharma H , SantraS, DebnathJ, AntonioT, ReithM, DuttaA. Flexible and biomimetic analogs of triple uptake inhibitor 4-((((3S,6S)-6-benzhydryltetrahydro-2h-pyran-3-yl)amino)methyl)phenol: synthesis, biological characterization, and development of a pharmacophore model. Bioorg. Med. Chem.22 (1), 311–324 (2014).
   PubMed Web of Science ®Google Scholar
• Basile AS , JanowskyA, GolembiowskaKet al. Characterization of the antinociceptive actions of bicifadine in models of acute, persistent, and chronic pain. J. Pharmacol. Exp. Ther.321 (3), 1208–1225 (2007).
   PubMed Web of Science ®Google Scholar
• Krieter PA , GohdesM, MusickTJ, DuncansonFP, BridsonWE. Pharmacokinetics, disposition, and metabolism of bicifadine in humans. Drug Metab. Dispos.36 (2), 252–259 (2008).
   PubMed Web of Science ®Google Scholar
• Andersen PH . The dopamine inhibitor GBR 12909: selectivity and molecular mechanism of action. Eur. J. Pharmacol.166 (3), 493–504 (1989).
   PubMed Web of Science ®Google Scholar
• Maryanoff BE , MccomseyDF, GardockiJFet al. Pyrroloisoquinoline antidepressants. 2. In-depth exploration of structure-activity relationships. J. Med. Chem.30 (8), 1433–1454 (1987).
   PubMed Web of Science ®Google Scholar
• Moldt P , WatjenF. US5736556 A (1998).
   Google Scholar
• Huot P , FoxSH, BrotchieJM. Monoamine reuptake inhibitors in Parkinson’s disease. Parkinson’s Disease2015, 1–71 (2015).
   Web of Science ®Google Scholar
• Skolnick P , KrieterP, TizzanoJet al. Preclinical and clinical pharmacology of DOV 216,303, a “triple” reuptake inhibitor. CNS Drug Rev.12 (2), 123–134 (2006).
   PubMedGoogle Scholar
• Popik P , KrawczykM, GolembiowskaKet al. Pharmacological profile of the “triple” monoamine neurotransmitter uptake inhibitor, DOV 102,677. Cell Mol. Neurobiol.26 (4–6), 857–873 (2006).
   PubMed Web of Science ®Google Scholar
• Bymaster FP , GolembiowskaK, KowalskaM, ChoiYK, TaraziFI. Pharmacological characterization of the norepinephrine and dopamine reuptake inhibitor EB-1020: implications for treatment of attention-deficit hyperactivity disorder. Synapse66 (6), 522–532 (2012).
   PubMed Web of Science ®Google Scholar
• Miller S , StensbolTB. US20100144788 A1 (2010).
   Google Scholar
• Bang-Andersen B , RuhlandT, JorgensenMet al. Discovery of 1-[2-(2,4-dimethylphenylsulfanyl)phenyl]piperazine (Lu AA21004): a novel multimodal compound for the treatment of major depressive disorder. J. Med. Chem.54 (9), 3206–3221 (2011).
   PubMed Web of Science ®Google Scholar
• Shaw AM , BoulesM, ZhangYet al. Antidepressant-like effects of novel triple reuptake inhibitors, PRC025 and PRC050. Eur. J. Pharmacol.555 (1), 30–36 (2007).
   PubMed Web of Science ®Google Scholar
• Liang Y , ShawAM, BoulesMet al. Antidepressant-like pharmacological profile of a novel triple reuptake inhibitor, (1s,2s)-3-(methylamino)-2-(naphthalen-2-yl)-1-phenylpropan-1-ol (PRC200-SS). J. Pharmacol. Exp. Ther.327 (2), 573–583 (2008).
   PubMed Web of Science ®Google Scholar
• Bennett BA , WichemsCH, HollingsworthCKet al. Novel 2-substituted cocaine analogs: uptake and ligand binding studies at dopamine, serotonin and norepinephrine transport sites in the rat brain. J. Pharmacol. Exp. Ther.272 (3), 1176–1186 (1995).
   PubMed Web of Science ®Google Scholar
• Shao L , HewittMC, WangFet al. Discovery of n-methyl-1-(1-phenylcyclohexyl)ethanamine, a novel triple serotonin, norepinephrine and dopamine reuptake inhibitor. Bioorg. Med. Chem. Lett.21 (5), 1434–1437 (2011).
   PubMed Web of Science ®Google Scholar
• Fang X , GuoL, JiaJet al. SKF83959 is a novel triple reuptake inhibitor that elicits anti-depressant activity. Acta. Pharmacol. Sin.34 (9), 1149–1155 (2013).
   PubMed Web of Science ®Google Scholar
• Han Y , HanM, ShinD, SongC, HahnHG. Exploration of novel 3-substituted azetidine derivatives as triple reuptake inhibitors. J. Med. Chem.55 (18), 8188–8192 (2012).
   PubMed Web of Science ®Google Scholar
• Shao L , HewittMC, MalcolmSCet al. Synthesis and pharmacological characterization of bicyclic triple reuptake inhibitor 3-aryl octahydrocyclopenta[c]pyrrole analogues. J. Med. Chem.54 (15), 5283–5295 (2011).
   PubMed Web of Science ®Google Scholar
• Iversen L , GibbonsS, TrebleR, SetolaV, HuangXP, RothBL. Neurochemical profiles of some novel psychoactive substances. Eur. J. Pharmacol.700 (1–3), 147–151 (2013).
   PubMed Web of Science ®Google Scholar
• Zhou J , HeR, JohnsonKM, YeY, KozikowskiAP. Piperidine-based nocaine/modafinil hybrid ligands as highly potent monoamine transporter inhibitors: efficient drug discovery by rational lead hybridization. J. Med. Chem.47 (24), 5821–5824 (2004).
   PubMed Web of Science ®Google Scholar
• Gu XH , YuH, JacobsonAEet al. Design, synthesis, and monoamine transporter binding site affinities of methoxy derivatives of indatraline. J. Med. Chem.43 (25), 4868–4876 (2000).
   PubMed Web of Science ®Google Scholar
• Aluisio L , LordB, BarbierAJet al. In-vitro and in-vivo characterization of JNJ-7925476, a novel triple monoamine uptake inhibitor. Eur. J. Pharmacol.587 (1–3), 141–146 (2008).
   PubMed Web of Science ®Google Scholar
• Lee KH , ParkCE, MinKHet al. Synthesis and pharmacological evaluation of 3-aryl-3-azolylpropan-1-amines as selective triple serotonin/norepinephrine/dopamine reuptake inhibitors. Bioorg. Med. Chem. Lett.20 (18), 5567–5571 (2010).
   PubMed Web of Science ®Google Scholar
• Lucas MC , WeikertRJ, CarterDSet al. Design, synthesis, and biological evaluation of new monoamine reuptake inhibitors with potential therapeutic utility in depression and pain. Bioorg. Med. Chem. Lett.20 (18), 5559–5566 (2010).
   PubMed Web of Science ®Google Scholar
• Axford L , BootJR, HottenTMet al. Bicyclo[2.2.1]heptanes as novel triple re-uptake inhibitors for the treatment of depression. Bioorg. Med. Chem. Lett.13 (19), 3277–3280 (2003).
   PubMed Web of Science ®Google Scholar
• Shao L , WangF, MalcolmSCet al. Synthesis and pharmacological evaluation of 4-(3,4-dichlorophenyl)-n-methyl-1,2,3,4-tetrahydronaphthalenyl amines as triple reuptake inhibitors. Bioorg. Med. Chem.19 (1), 663–676 (2011).
   PubMed Web of Science ®Google Scholar
• Bettati M , CavanniP, Di FabioRet al. Oxa-azaspiro derivatives: a novel class of triple re-uptake inhibitors. Chem. Med. Chem.5 (3), 361–366 (2010).
   Google Scholar
• Delorenzo C , LichensteinS, SchaeferKet al. SEP-225289 serotonin and dopamine transporter occupancy: a PET study. J. Nucl. Med.52 (7), 1150–1155 (2011).
   PubMed Web of Science ®Google Scholar
• Culig J , EhsanullahRS, HallettC, IliopoulouA, MathesonI, TurnerP. A clinical pharmacological comparison of diclofensine (Ro 8–4650) with nomifensine and amitriptyline in normal human volunteers. Br. J. Clin. Pharmacol.15 (5), 537–543 (1983).
   PubMed Web of Science ®Google Scholar
• Pearce RK , SmithLA, JacksonMJ, BanerjiT, Scheel-KrugerJ, JennerP. The monoamine reuptake blocker brasofensine reverses akinesia without dyskinesia in MPTP-treated and levodopa-primed common marmosets. Mov. Disord.17 (5), 877–886 (2002).
   PubMed Web of Science ®Google Scholar
• Zhu M , WhiganDB, ChangSY, DockensRC. Disposition and metabolism of [14c]brasofensine in rats, monkeys, and humans. Drug Metab. Dispos.36 (1), 24–35 (2008).
   PubMed Web of Science ®Google Scholar
• Wilens TE , KlintT, AdlerLet al. A randomized controlled trial of a novel mixed monoamine reuptake inhibitor in adults with ADHD. Behav. Brain Funct.4, 24 (2008).
   PubMed Web of Science ®Google Scholar
• Learned S , GraffO, RoychowdhurySet al. Efficacy, safety, and tolerability of a triple reuptake inhibitor GSK372475 in the treatment of patients with major depressive disorder: two randomized, placebo- and active-controlled clinical trials. J. Psychopharmacol.26 (5), 653–662 (2012).
   PubMed Web of Science ®Google Scholar
• Thatte U . NS-2330 (Neurosearch). Curr. Opin. Investig. Drugs2 (11), 1592–1594 (2001).
   PubMedGoogle Scholar
• Sorensen G , HusumH, BrennumLTet al. Addiction-related effects of DOV 216,303 and cocaine: a comparative study in the mouse. Basic Clin. Pharmacol. Toxicol.114 (6), 451–459 (2014).
   PubMed Web of Science ®Google Scholar
• Lu AA24530 shows positive results in major depressive disorder Phase II study. http://investor.lundbeck.com/releasedetail.cfm?ReleaseID=608619
   Google Scholar
• Takeda and Lundbeck announce FDA approval of brintellix™ (vortioxetine) for treatment of adults with major depressive disorder. http://investor.lundbeck.com/releasedetail.cfm?ReleaseID=794050
   Google Scholar
• Gibb A , DeeksED. Vortioxetine: first global approval. Drugs74 (1), 135–145 (2014).
   PubMed Web of Science ®Google Scholar
• Hanna MM , EidNM, GeorgeRF, SafwatHM. Synthesis of some tropane derivatives of anticipated activity on the reuptake of norepinephrine and/or serotonin. Bioorg. Med. Chem.15 (24), 7765–7772 (2007).
   PubMed Web of Science ®Google Scholar
• Guha M , HeierA, PriceSet al. Assessment of biomarkers of drug-induced kidney injury in cynomolgus monkeys treated with a triple reuptake inhibitor. Toxicol. Sci.120 (2), 269–283 (2011).
   PubMed Web of Science ®Google Scholar
• Bennett BA , HollingsworthCK, MartinRSet al. Prolonged dopamine and serotonin transporter inhibition after exposure to tropanes. Neuropharmacology37 (1), 123–130 (1998).
   PubMed Web of Science ®Google Scholar
• Daunais JB , HartSL, SmithHRet al. Long-acting blockade of biogenic amine transporters in rat brain by administration of the potent novel tropane 2beta-propanoyl-3beta-(2-naphthyl)-tropane. J. Pharmacol. Exp. Ther.285 (3), 1246–1254 (1998).
   PubMed Web of Science ®Google Scholar
• Dawson P , Opacka-JuffryJ, MoffattJDet al. The effects of benzofury (5-APB) on the dopamine transporter and 5-HT2-dependent vasoconstriction in the rat. Prog. Neuropsychopharmacol. Biol. Psychiatry48, 57–63 (2014).
   PubMed Web of Science ®Google Scholar
• Bogeso KP , ChristensenAV, HyttelJ, LiljeforsT. 3-Phenyl-1-indanamines. Potential antidepressant activity and potent inhibition of dopamine, norepinephrine, and serotonin uptake. J. Med. Chem.28 (12), 1817–1828 (1985).
   PubMed Web of Science ®Google Scholar
• Lengyel K , PieschlR, StrongTet al. Ex vivo assessment of binding site occupancy of monoamine reuptake inhibitors: methodology and biological significance. Neuropharmacology55 (1), 63–70 (2008).
   PubMed Web of Science ®Google Scholar
• Schenk S . Effects of GBR 12909, WIN 35,428 and indatraline on cocaine self-administration and cocaine seeking in rats. Psychopharmacology (Berl.)160 (3), 263–270 (2002).
   PubMed Web of Science ®Google Scholar
• Micheli F , CavanniP, AndreottiDet al. 6-(3,4-Dichlorophenyl)-1-[(methyloxy)methyl]-3-azabicyclo[4.1.0]heptane: a new potent and selective triple reuptake inhibitor. J. Med. Chem.53 (13), 4989–5001 (2010).
   PubMed Web of Science ®Google Scholar
• Beer B , StarkJ, KrieterPet al. DOV 216,303, a “triple” reuptake inhibitor: safety, tolerability, and pharmacokinetic profile. J. Clin. Pharmacol.44 (12), 1360–1367 (2004).
   PubMed Web of Science ®Google Scholar
• Tran P , SkolnickP, CzoborPet al. Efficacy and tolerability of the novel triple reuptake inhibitor amitifadine in the treatment of patients with major depressive disorder: a randomized, double-blind, placebo-controlled trial. J. Psychiatr. Res.46 (1), 64–71 (2012).
   PubMed Web of Science ®Google Scholar
• Schreiber R , LewR, HardyL, CremersT, FangQK, CampbellU. Pharmacological characterization of the triple monoamine transporter inhibitor SEP-225289. Presented at : Meeting of Society for Neuroscience, Chicago, IL, USA, 17–21October 2009.
   Google Scholar
• Comley RA , SalinasCA, SlifsteinMet al. Monoamine transporter occupancy of a novel triple reuptake inhibitor in baboons and humans using positron emission tomography. J. Pharmacol. Exp. Ther.346 (2), 311–317 (2013).
   PubMed Web of Science ®Google Scholar
• Risinger R , BhagwagarZ, LuoFet al. Evaluation of safety and tolerability, pharmacokinetics, and pharmacodynamics of BMS-820836 in healthy subjects: a placebo-controlled, ascending single-dose study. Psychopharmacology (Berl.)231 (11), 2299–2310 (2014).
   PubMed Web of Science ®Google Scholar
• Tran P , SkolnickP, CzoborPet al. Efficacy and tolerability of the novel triple reuptake inhibitor amitifadine in the treatment of patients with major depressive disorder: a randomized, double-blind, placebo-controlled trial. J. Psychiatr. Res.46 (1), 64–71 (2012).
   PubMed Web of Science ®Google Scholar
• Lane RM . Antidepressant drug development: focus on triple monoamine reuptake inhibition. J. Psychopharmacol.29 (5), 526–544 (2015).
   PubMed Web of Science ®Google Scholar
• Czobor P , SkolnickP. The secrets of a successful clinical trial: compliance, compliance, and compliance. Mol. Interv.11 (2), 107–110 (2011).
   PubMed Web of Science ®Google Scholar
• Bourdet DL , TsurudaPR, ObedencioGP, SmithJA. Prediction of human serotonin and norepinephrine transporter occupancy of duloxetine by pharmacokinetic/pharmacodynamic modeling in the rat. J. Pharmacol. Exp. Ther.341 (1), 137–145 (2012).
   PubMed Web of Science ®Google Scholar
• Ding YS , NaganawaM, GallezotJDet al. Clinical doses of atomoxetine significantly occupy both norepinephrine and serotonin transports: implications on treatment of depression and ADHD. Neuroimage86, 164–171 (2014).
   PubMed Web of Science ®Google Scholar
• Smith JA , PatilD, DanielsOet al. Preclinical to clinical translation of CNS transporter occupancy of TD-9855, a novel norepinephrine and serotonin reuptake inhibitor. Int. J. Neuropsychopharmacol.18 (2), (2015).
   Web of Science ®Google Scholar
• Learned-Coughlin SM , BergstromM, SavitchevaI, AscherJ, SchmithVD, LangstromB. In vivo activity of bupropion at the human dopamine transporter as measured by positron emission tomography. Biol. Psychiatry54 (8), 800–805 (2003).
   PubMed Web of Science ®Google Scholar
• Appel L , BergstromM, Buus LassenJ, LangstromB. Tesofensine, a novel triple monoamine re-uptake inhibitor with anti-obesity effects: dopamine transporter occupancy as measured by PET. Eur. Neuropsychopharmacol.24 (2), 251–261 (2014).
   PubMed Web of Science ®Google Scholar
• George M , RajaramM, ShanmugamE. New and emerging drug molecules against obesity. J. Cardiovasc. Pharmacol. Ther.19 (1), 65–76 (2014).
   PubMed Web of Science ®Google Scholar
• Tizzano JP , StriblingDS, Perez-TilveDet al. The triple uptake inhibitor (1r,5s)-(+)-1-(3,4-dichlorophenyl)-3-azabicyclo[3.1.0] hexane hydrochloride (DOV 21947) reduces body weight and plasma triglycerides in rodent models of diet-induced obesity. J. Pharmacol. Exp. Ther.324 (3), 1111–1126 (2008).
   PubMed Web of Science ®Google Scholar
• Dov 21,947 demonstrates significant body weight and BMI reductions in drug- compliant subjects in Phase Ib clinical study. www.sec.gov/Archives/edgar/data/1066833/000114420407051174/v088668_ex99–1.htm
   Google Scholar
• O’tousa DS , WarnockKT, MatsonLMet al. Triple monoamine uptake inhibitors demonstrate a pharmacologic association between excessive drinking and impulsivity in high-alcohol-preferring (HAP) mice. Addict. Biol.20 (2), 236–247 (2013).
   PubMed Web of Science ®Google Scholar
• Economidou D , TheobaldDE, RobbinsTW, EverittBJ, DalleyJW. Norepinephrine and dopamine modulate impulsivity on the five-choice serial reaction time task through opponent actions in the shell and core sub-regions of the nucleus accumbens. Neuropsychopharmacology37 (9), 2057–2066 (2012).
   PubMed Web of Science ®Google Scholar